Each capsule contains: Cinnarizine 75 mg.
Pharmacology: Pharmacodynamics: Cinnarizine is a piperazine derivative with antihistamine, sedative, and calcium-channel blocking activity.
Pharmacokinetics: Cinnarizine is absorbed from the gastro-intestinal tract, peak plasma concentrations occurring 2 to 4 hours after oral administration. It undergoes metabolism and has half-life of 3 to 6 hours. Cinnarizine is excreted in the feces mainly as unchanged drug, and in the urine predominantly as metabolites.
For prophylaxis and maintenance therapy for symptoms of cerebrovascular spasm and arteriosclerotic disorders due to aging, Meniere's Disease, Labyrinthine disturbances and motion sickness.
Cerebral circulation disorder: 1 capsule once daily.
Peripheral circulation disorders: 2-3 capsules three times a day.
Vestibular disturbances: 1 capsule once daily.
Motion sickness: 1 capsule ½ hour before traveling. To be repeated every 6 hours. Should be taken with food or as prescribed by the physician.
There is no specific antidote. For any overdose, the treatment is symptomatic and supportive care.
Patients with known hypersensitivity to cinnarizine.
Should not be given to premature infants or neonates.
Cinnarizine should be used during pregnancy only if the therapeutic benefits justify the potential risks for the fetus.
Nursing should be discouraged in women using cinnarizine.
Slight drowsiness to deep sleep, lassitude and incoordination, headache, psychomotor impairment, dry mouth, thickened respiratory-tract secretions, blurred vision, urinary difficulty or retention, constipation and increased gastric reflux. There have been rare reports of extrapyramidal symptoms which are sometimes associated with depressive feelings.
Sedating antihistamines may enhance the sedative effects of CNS depressants including alcohol, barbiturates, hypnotics, opioid analgesic, anxiolytic sedatives, and antipsychotics. Sedative interactions apply to a lesser extent with the non-sedative antihistamines; they do not appear to potentiate the effects of alcohol, but it should be avoided in excess.
Store at temperatures not exceeding 30°C.
N07CA02 - cinnarizine ; Belongs to the class of antivertigo preparations.
Dizzinon Forte cap 75 mg
100's
Sign Out
